Back to Browse Journals » Current Biomarker Findings » Volume 3

Urinary biomarkers of diabetic nephropathy

Authors Mehta S, Cabrera VJ, Upputalla R, Jim B

Received 15 August 2013

Accepted for publication 26 September 2013

Published 25 November 2013 Volume 2013:3 Pages 67—78


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Swati Mehta,1 Valerie Jorge Cabrera,2 Roshni Upputalla,2 Belinda Jim2

1Department of Medicine, James J Peters VA Medical Center, Bronx, NY, USA; 2Division of Nephrology, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Abstract: The fervent search for an early biomarker for diabetic nephropathy is continuing because this entity has become the leading cause of end-stage renal disease in many countries. Novel biomarkers are being described in a high-speed manner. Using urine as a biological source is especially appealing given its ease of collection and its ability to serve as a direct conduit to the site of injury. We begin by briefly discussing the merits and pitfalls of our gold standard of microalbuminuria, and shift quickly to several promising nontraditional protein and messenger (m)RNA biomarkers. The quality of the evidence for using urinary podocyte as a marker will be described. Exploring entire sets of protein in humans in terms of proteomics has been a favorite approach in the last decade because the technology of protein separation and mass spectrometry allows for the unbiased search for new biomarkers. Isolating urinary microRNA may become yet another preferred method because these small, noncoding mRNA that regulate gene expression are particularly stable and apt for biomarker studies. Finally, the latest development is perhaps the study of exosomes, which are nanometer particles derived from the fusion of internal vesicles to the plasma membrane. These particles harbor protein, mRNA, and microRNA that may be isolated for further study. With the advent of newer technologic approaches, we hope that these newly discovered biomarkers will be rigorously tested in large, prospective, clinical trials so they can be implemented in clinical practice.

Keywords: diabetes, predictor, proteinuria, albuminuria, exosomes, proteomics, podocyte

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Deep brain stimulation for the treatment of Parkinson’s disease: efficacy and safety

Pouratian N, Thakkar S, Kim W, Bronstein JM

Degenerative Neurological and Neuromuscular Disease 2012, 2:107-117

Published Date: 4 September 2012

Principles of medical ethics: implications for the disclosure of medical errors

Hannawa AF

Medicolegal and Bioethics 2012, 2:1-11

Published Date: 27 July 2012

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

Izchak Kohen, Paula E Lester, Sum Lam

Neuropsychiatric Disease and Treatment 2010, 6:47-58

Published Date: 2 March 2010

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

M Gabrovska, F Geurs, S Ponette, et al

Hepatic Medicine: Evidence and Research 2009, 1:9-12

Published Date: 30 October 2009

Exforge® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact

Jean-Marie Krzesinski, Eric P Cohen

Core Evidence 2009, 4:1-11

Published Date: 17 June 2009